TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04624373

Intervention type: OTHER
Intervention: Molecular analysis of surnatant
Description: The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing).

Intervention type: OTHER
Intervention: Molecular analysis of surnatant
Description: The interventional pulmonologist selects the most suspect node. The corresponding TBNA is placed in Cytolyt and tagged using a sticker to indicate the specimen from which supernatant must be saved after the initial spin.~The supernatant is transferred to the Laboratoire de Biologie Médicale Oncologique where it undergoes a further hard spin. The remaining supernatant is stored at -80°C before to send it to Foundation One for DNA extraction from 3 ml of supernatant and genotyping.~Two 7,5 mL blood tubes are transferred to the laboratory to extract plasma. Plasma was stored at -80°C and then sent to Foundation One for DNA extraction from 2 mL of plasma and genotyping.~10 slides from the cell block are shipped to Foundation One. These specimens are tested by FoundationOne®CDX (tissue), and FoundationOne®Liquid (supernatant and plasma) for genomic and TMB analyses (hybrid-capture based next generation sequencing).
Study: NCT04700046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine 167 mg
Description: Mexiletine 167 mg (equivalent to mexiletine HCl 200 mg) immediate release, oral capsules.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules contain the same ingredients as the active formulation with the exception of mexiletine
Study: NCT06280326

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunflower oil
Description: In the experimental group, patch removal will be performed using sunflower oil.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slicone based spray
Description: In the control group, clinical routine procedure will be used to remove the patch (silicone based spray.
Study: NCT05184686

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: noise expose
Description: simulate noise expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: noise expose
Description: simulate noise expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: noise expose
Description: simulate noise expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: noise expose
Description: simulate noise expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RF expose
Description: simulate RF expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RF expose
Description: simulate RF expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RF expose
Description: simulate RF expose environments

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: RF expose
Description: simulate RF expose environments
Study: NCT05640466

Intervention type: DEVICE
Group type: OTHER
Intervention: Reduction and fixation of metatarsal neck fracture by metaizeau's technique
Description: Reduction and fixation of metatarsal neck fracture by metaizeau's technique
Study: NCT05214196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)
Description: SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)
Description: SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hypochlorous Acid 0.02% Soln,Top (Crystaline) (HClO)
Description: SARS-CoV-2 sample was obtained from COVID-19 patients by rinsing the mouth and throat with 5 ml of isotonic saline before and 30 minutes after rinsing. In the hypochlorous acid group, 20 ml of HClO was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the povidone-iodine group, 20 ml of PVP-I was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants. In the saline group, 20 ml of saline was asked to be rinsed in the mouth and throat for 30 seconds in 25 participants.
Study: NCT05193240

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: preliminary swallowing test
Description: Patients will be included before the surgery. During this inclusion visit, we will perform a preoperative swallowing test.~Immediately after surgery (H2-H24 after extubation), we will perform a preliminary swallowing test, an ultrasound examination of the vocal cords and a nasofibroscopy to determine the mobility of the vocal cords. A physiotherapist will carry out the first two assessments. An ENT physician will perform the nasofibroscopy. The ENT physician performing the nasofibroscopy will not know the conclusions of the tests carried out by the physiotherapist immediately after the operation.~At last, on day 4 after extubation, we will repeat the preliminary swallowing test and the ultrasound examination to measure the evolution of cord mobility.~30 days after the surgery, we will realize a follow-up on medical file and mark the end of the research.
Study: NCT05794763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led Group Intervention
Description: A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Led Group Intervention
Description: A four-week dissonance-based program where individuals with body image concerns complete verbal, written, and behavioral activities. The program consists of four 60-minute sessions
Study: NCT06059066

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard number of injection sites
Description: 200 units or 300 units BTX-A reconstituted in 20 mL normal saline, injected into the bladder detrusor in 20 separate injections of 1 mL including the trigone.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reduced number of injection sites
Description: 200 units or 300 units BTX-A reconstituted in 5 mL normal saline, injected into the bladder detrusor in 5 separate injections of 1 mL including the trigone.
Study: NCT05254535

Intervention type: OTHER
Group type: OTHER
Intervention: I-SITE
Description: I-SITE includes coaching facilitation, technical assistance, and an online toolkit to allow primary care clinics to tailor the integration of teleophthalmology into their daily workflows based on each clinic's unique needs and resources. The program includes a series of coaching sessions between a skilled practice facilitator and clinical personnel at each health system.
Study: NCT04602377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 25 MG/ML [Keytruda]
Description: Pembrolizumab (200mg flat dose) will be administred in combinaison with PAVEP chemotherapy for the first 6 cycles (21-day cycle)~Then, Pembrolizumab (200mg flat dose) will be administred in monotherapy until one year for patients with complete response and up to two years for patients with Stable disease or Progression response after the end of first-sequence therapy (PAVEP chemotherapy +/- High dose chemotherapy) or until disease progression.
Study: NCT02549560

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
Study: NCT05275283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEEP
Description: 6 cmH2O of PEEP
Study: NCT04530409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early-Corticosteroids
Description: early use of dexamethasone/Methylprednisolone as early as laboratory evidence of high inflammatory markers
Study: NCT04788498

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoendoscpoic single site surgery LESS
Description: • A SILS Port (Covidien®) with three access inlets will be inserted into the abdominal cavity using a Heaney clamp

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional multiport laparoscopy
Description: • It will be performed using a three-port system using a closed technique on the umbilicus, left and right lower quadrant area.
Study: NCT05156632

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dosage COVID-19 Vaccine,Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd..600SU Inactivated SARS-COV-2 virus in 0·5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dosage COVID-19 Vaccine,Inactivated
Description: The COVID-19 vaccine,inactivated was manufactured by Sinovac Research\& Development Co., Ltd.1200SU inactivated virus in 0.5 mL of aluminium hydroxide solution per injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-comparator group
Description: The composition is aluminium hydroxide with no antigen ,0 SU/0.5 mL,The appearance of the placebo is consistent with the vaccine, which is a milky-white suspension.
Study: NCT04725825

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham needling
Description: During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
Study: NCT04570111

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MOD Diet
Description: The macro-optimized diet alters the timing of macronutrient intake to provide fewer carbohydrates at breakfast, while maintaining recommended amounts of macronutrients delivered throughout the course of the day

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Diet
Description: The standard care diet provides macronutrients within standard amounts (40% carbohydrate, 20% protein, 40% fat) at all meals and snacks per day.
Study: NCT05813717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986325
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT05202717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PHENIX U4+
Description: The newly developed domestic PHENIX U4+ is relatively small in size. In addition to the smooth muscle stimulation function of the traditional therapy device, its electrical stimulation waveform setting can also stimulate the striated muscle, and adds more than 10 A3 reflex treatment options, which can inhibit Urinary reflex, resulting in symptoms related to urinary incontinence in the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional pelvic floor treatment instrument
Description: Traditional pelvic floor treatment instrument commonly used in clinical practice
Study: NCT05882669

Intervention type: OTHER
Intervention: Questionnaire administration
Description: All study participants will be surveyed with the EQ-5D-5L questionnaire to measure their quality of life indicators before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the WOMAC questionnaire to measure their functional outcomes before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period); the costs questionnaire to measure direct and indirect costs borne by patients because of their condition before the primary total knee arthroplasty and after the surgery (on 4 dates over a 1-year period).
Study: NCT02649153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: smoked plum
Description: Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gum chewing
Description: Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
Study: NCT05555511

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients will not receive N-Acetylcystiene and will receive standard care according to our institutional protocol
Study: NCT05876715

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Description: This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
Study: NCT05698823

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumoral Treatment
Description: The Lumoral treatment -device is a CE-marked antibacterial home-use device for the treatment and prevention of oral diseases caused by bacteria. It is used in combination with a CE-marked mouth rinse called Lumorinse.
Study: NCT03831425

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10
Description: 6 week trial of either treatment with CoenzymeQ.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 6 week trial of either treatment with Placebo
Study: NCT05356117

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT) and Protein Supplementation (PS)
Description: Aerobic and resistance exercise with orally consumed pre-packed protein supplement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Description: Aerobic and resistance exercise

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control (AC
Description: Stretching
Study: NCT05577078

Intervention type: PROCEDURE
Intervention: Transcatheter edge-to-edge repair (TEER)
Description: Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation
Study: NCT06456450

Intervention type: BIOLOGICAL
Intervention: Biological Treatment for severe asthma patients
Description: Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

Intervention type: BIOLOGICAL
Intervention: Biological Treatment for severe asthma patients
Description: Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

Intervention type: BIOLOGICAL
Intervention: Biological Treatment for severe asthma patients
Description: Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

Intervention type: BIOLOGICAL
Intervention: Biological Treatment for severe asthma patients
Description: Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance

Intervention type: BIOLOGICAL
Intervention: Biological Treatment for severe asthma patients
Description: Biological treatment for severe asthma available in Taiwan and is covered by covered by National Health Insurance
Study: NCT04242511

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of tuberculosis medications level
Description: Measurement of tuberculosis medication levels at 2 hours post-dose

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of tuberculosis medications level
Description: Measurement of tuberculosis medication levels at 2 hours post-dose
Study: NCT05462795

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule
Description: 10 cc of blood is collected at one time point, which is prior to biopsy procedure

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection
Description: 10 cc of blood is collected at three time points: 1) before surgery; 2) 4-6 weeks post surgery; and 3) 6 months post surgery

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer
Description: 10 cc of blood is collected at one time point

Intervention type: DIAGNOSTIC_TEST
Intervention: Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease
Description: 30 cc of blood is collected at one time point
Study: NCT04828694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BICX104
Description: Erodable implantable pellet containing 1 g naltrexone and 11 mg magnesium stearate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vivitrol
Description: Intramuscular injection containing 380 mg of naltrexone.
Study: NCT04858139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactate
Description: Intravenous injection (20 min), 300 mmol/L, 1mmol/Kg body weight,

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection (20 min)
Study: NCT04687449

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin therapy
Description: Clear capsules (made of vegetable cellulose) with turmeric extract (500 mg, 95% curcuminoids), Bioperine (5 mg, improves absorption), and inactive ingredients (microcrystalline cellulose, vegetable magnesium stearate, silicon dioxide).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Clear capsules (made of vegetable cellulose) with inactive ingredients (lactose monohydrate and food color); the capsules will be matched in size and color of the content to the preparation used in the Curcumin capsule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard of care for COPD.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard of care for COPD.
Study: NCT05536609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epineural suture
Description: 2 or three sutures

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-operative treatment
Description: The injured finger is protected in a plaster cast
Study: NCT05541211

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coeliac plexus neurolysis
Description: Coeliac plexus neurolysis (CPN) will be performed bilaterally. Neurolytic solution will be injected around the coeliac plexus (a network of nerves located in the abdomen).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Splanchnic nerve neurolysis
Description: Splanchnic nerve neurolysis (SNN) will be performed bilaterally. Neurolytic solution will be injected around the splanchnic nerves (a nerve located at thoracic trunk).
Study: NCT05845216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACTIVE Transcranial photobiomodulation (tPBM)
Description: fMRI records before and after ACTIVE Transcranial photobiomodulation (tPBM)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Transcranial photobiomodulation (tPBM)
Description: fMRI records before and after SHAM Transcranial photobiomodulation (tPBM)
Study: NCT05843123

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support a
Description: Invasive mechanical ventilation mode

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory support b
Description: Invasive mechanical ventilation mode
Study: NCT05240352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS
Description: Subjects will receive active dose (constant current intensity of 2mA) from the tDCS device for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS
Description: Subjects will receive a dose from a sham-tDCSthat is, a device which delivers a different pattern of electric current for 30 minutes per session for two weeks with no sessions on Saturday and Sunday (Monday to Friday), and one additional session two and four weeks later
Study: NCT05683249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRCT-101-SR
Description: NRCT-101SR is a sustained release formulation. Subjects ≥ 50 kg LBM receive a total of four 500 mg tablets/day and subjects \< 50kg LBM receive a total of four 375 mg tablets per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo